Literature DB >> 17913854

Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

K M Wahidur Rahman1, Shadan Ali, Amro Aboukameel, Sanila H Sarkar, Zhiwei Wang, Philip A Philip, Wael A Sakr, Avraham Raz.   

Abstract

Constitutive activation of Akt or nuclear factor-kappaB (NF-kappaB) has been reported to play a role in de novo resistance of cancer cells to chemotherapeutic agents, which is a major cause of treatment failure in cancer chemotherapy. Previous studies have shown that 3,3'-diindolylmethane (DIM), a major in vivo acid-catalyzed condensation product of indole-3-carbinol, is a potent inducer of apoptosis, inhibitor of tumor angiogenesis, and inactivator of Akt/NF-kappaB signaling in breast cancer cells. However, little is known regarding the inactivation of Akt/NF-kappaB that leads to chemosensitization of breast cancer cells to chemotherapeutic agents, such as Taxotere. Therefore, we examined whether the inactivation Akt/NF-kappaB signaling caused by B-DIM could sensitize breast cancer cells to chemotherapeutic agents both in vitro and in vivo. MDA-MB-231 cells were simultaneously treated with 15 to 45 micromol/L B-DIM and 0.5 to 1.0 nmol/L Taxotere for 24 to 72 h. Cell growth inhibition assay, apoptosis assay, electrophoretic mobility shift assay, and Western blotting were done. The combination treatment of 30 micromol/L B-DIM with 1.0 nmol/L Taxotere elicited significantly greater inhibition of cell growth compared with either agent alone. The combination treatment induced greater apoptosis in MDA-MB-231 cells compared with single agents. Moreover, we found that NF-kappaB activity was significantly decreased in cells treated with B-DIM and Taxotere. We also have tested our hypothesis using transfection studies, followed by combination treatment with B-DIM/Taxotere, and found that combination treatment significantly inhibited cell growth and induced apoptosis in MDA-MB-231 breast cancer cells mediated by the inactivation of NF-kappaB, a specific target in vitro and in vivo. These results were also supported by animal experiments, which clearly showed that B-DIM sensitized the breast tumors to Taxotere, which resulted in greater antitumor activity mediated by the inhibition of Akt and NF-kappaB. Collectively, our results clearly suggest that inhibition of Akt/NF-kappaB signaling by B-DIM leads to chemosensitization of breast cancer cells to Taxotere, which may contribute to increased growth inhibition and apoptosis in breast cancer cells. The data obtained from our studies could be a novel breakthrough in cancer therapeutics by using nontoxic agents, such as B-DIM, in combination with other conventional therapeutic agents, such as Taxotere.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913854     DOI: 10.1158/1535-7163.MCT-07-0336

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  41 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.

Authors:  Massod Rahimi; Kai-Ling Huang; Careen K Tang
Journal:  Cancer Lett       Date:  2010-03-17       Impact factor: 8.679

Review 3.  Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy.

Authors:  Aamir Ahmad; Bernhard Biersack; Yiwei Li; Dejuan Kong; Bin Bao; Rainer Schobert; Subhash B Padhye; Fazlul H Sarkar
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

4.  IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.

Authors:  Minghua Zou; Xianquan Zhang; Changhua Xu
Journal:  Cell Oncol (Dordr)       Date:  2015-10-28       Impact factor: 6.730

Review 5.  Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic.

Authors:  Sanjeev Banerjee; Dejuan Kong; Zhiwei Wang; Bin Bao; Gilda G Hillman; Fazlul H Sarkar
Journal:  Mutat Res       Date:  2011-06-15       Impact factor: 2.433

6.  Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Jacqueline M Schaffert; Bassel F El-Rayes; Philip A Philip; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2010-05       Impact factor: 4.429

7.  Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer.

Authors:  Xiuwei Zhang; Lin Fu; Dongwei Xue; Xiupeng Zhang; Fengxia Hao; Lingling Xie; Jiani He; Junda Gai; Yuhui Liu; Hongtao Xu; Qingchang Li; Enhua Wang
Journal:  Virchows Arch       Date:  2017-03-13       Impact factor: 4.064

8.  Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice.

Authors:  Fekadu Kassie; Stephen Kalscheuer; Ilze Matise; Linan Ma; Tamene Melkamu; Pramod Upadhyaya; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2009-07-22       Impact factor: 4.944

9.  3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.

Authors:  Sanjeev Banerjee; Zhiwei Wang; Dejuan Kong; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-06-16       Impact factor: 12.701

10.  3,3'-diindolylmethane rapidly and selectively inhibits hepatocyte growth factor/c-Met signaling in breast cancer cells.

Authors:  Holly L Nicastro; Gary L Firestone; Leonard F Bjeldanes
Journal:  J Nutr Biochem       Date:  2013-08-19       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.